Can scans and blood predict brain fog after radiation?
NCT ID NCT05087888
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether repeated MRI scans and blood tests could predict changes in thinking and memory after brain radiation. Researchers enrolled 9 adults with brain tumors who were scheduled for radiation. They collected blood samples and performed advanced MRI scans over time to see if these tests could signal early cognitive decline.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict and monitor cognitive decline after brain radiation, potentially guiding treatment adjustments.
- What could go wrong
- This was a very small, terminated study with only 9 participants, so results may not be reliable or generalizable. No treatment was tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
9 people
The number who actually took part.
- Started
-
Aug 2019
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients undergoing central nervous system (CNS) or head and neck (H\&N) radiotherapy with radiation exposure to the brain to investigate the pattern of neurocognitive changes in relation to brain dosimetry and associated imaging and biofluid biomarkers predictive of neurocognitive outcomes
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients must be age \>= 18 years * Patients must be planned for fractionated radiotherapy that will be delivered over at least 5 weeks and that will expose the brain to radiation * Patients must have Karnofsky performance status (KPS) \>= 80 * Patients must be able to obtain an MRI scan with gadolinium contrast * Female patients of childbearing age must not be pregnant as determined with a serum beta human chorionic gonadotropin (HCG) no greater than 14 days prior to study registration, or breast-feeding. (The exclusion is made because gadolinium may be teratogenic in pregnancy). Pregnancy tests are part of standard of care routine if a patient is receiving radiation treatment * Patient must be fluent enough in English to complete neurocognitive testing * Education of \>= 12 years (high school graduate or equivalent) by patient self-report * Patient is able to complete an in-person and electronic neurocognitive assessments (i.e. is alert and has the ability to comprehend and complete the assessments) * Patient has no history of psychiatric or medical conditions that would result in an inability to complete serial neurocognitive tests, severe claustrophobia, prior cerebrovascular event(s), degenerative neurological diagnoses (e.g., dementia, Parkinson's, multiple sclerosis \[MS\]) or severe psychiatric illness (e.g., schizophrenia) that may impact neurocognitive and imaging assessments Exclusion Criteria: * Previous brain radiation without comprehensive dosimetry records * Concurrent chemotherapy * Psychiatric or medical conditions that would result in inability to complete serial neurocognitive tests * Severe claustrophobia requiring sedative medications for the MRI * Prior cerebrovascular event(s) or degenerative neurological diagnoses (e.g., dementia, Parkinson's, MS) * Contraindication to gadolinium-based contrast administration for MRI (i.e. allergy to gadolinium or severe chronic kidney disease defined by estimated glomerular filtration rate \[eGFR\] \< 30 mL/min/1.73 m\^2, as per institutional policy)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Brain neoplasm are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental therapy aims to turn brain tumors against themselves
- Radiation-Free brain imaging for kids? ultrasound may offer a safer path
- AI and ultrasound join forces to spot muscle wasting in Brain-Injured ICU patients
- Brain wave decoding aims to shield memory during tumor surgery
- New hope for glioblastoma: drug infused directly into brain shows promise
- New combo attack on recurrent brain tumors shows promise in early trial